Track 07 of 9
Headache Medicine
CGRP antagonists, cluster headache and chronic migraine.
Migraine treatment has been revolutionized by the CGRP pathway, with four anti-CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab) for prevention and the gepant class (ubrogepant, rimegepant, atogepant, zavegepant nasal spray) bridging acute and preventive use. GCNN 2027 will review long-term real-world effectiveness and safety, switching algorithms, and emerging data on gepants in menstrual and vestibular migraine. The track will also cover ditans (lasmiditan), remote electrical neuromodulation and non-invasive vagal stimulation, cluster headache (galcanezumab, occipital nerve stimulation), and the persistent challenge of medication overuse headache.
Focus areas
- CGRP monoclonal antibodies: long-term safety, switching, pregnancy data
- Gepants: atogepant, rimegepant, ubrogepant, zavegepant nasal
- Lasmiditan and non-triptan acute therapy in cardiovascular risk
- Cluster headache: galcanezumab, occipital nerve and SPG stimulation
- Neuromodulation: REN, nVNS, eTNS in acute and preventive care
- Pediatric and adolescent migraine treatment paradigms
- Medication overuse headache: detoxification and bridging strategies